Reports indicate that in 2014, many more mature Israeli high-tech companies preferred an IPO to being acquired.
Israeli high-tech exits doubled to a record $15 billion in 2014. This has been by far the best-ever year for the country's high-tech and biomed sector in terms of exits.
In 2014, the stars were aligned exactly right for Israeli high-tech. The IPO window was open in the US and England due to the maturity of many Israeli companies and investors, the major availability of money for high-tech from buyers and investors, and of course the strength of Israeli high-tech that knew how to reinvent itself and adapt to the times.